Modified Release Formulation Development

Optimize your modified-release formulations.
Scientific Poster Spotlight
With a strong emphasis on science and innovation, we help reduce development risks for modified-release formulations. Read a summary of our scientific content featured at past events.

What are examples of different modified-release dosage forms?

Explore some of the types of modified release and sustained release dosage forms that we can help you address. Have a specific question about a modified release or sustained release dosage form? 

Gastro-retention 
dosage forms

Includes swellable tablets (monolithic, bilayer, trilayer) that keep the formulation in the stomach for an extended period to maximize the duration of absorption or therapeutic activity

Gastro-resistant
dosage forms

Enteric-coated tablets or capsules that prevent release of the drug in the stomach and/or upper gastrointestinal (GI) tract.

Extended release
dosage forms

Matrix tablets, coated tablets, or multiparticulates that allow for extended or sustained release. 

With extended-release dosage forms, we can adjust the in-vivo release profile of the drug, enabling once-daily dosing.

Pulsatile release
dosage forms

Pulsatile release dosage forms are beneficial for drugs where time-dependent dosing is required or those that undergo first-pass metabolism.

Biphasic release
dosage forms

Biphasic release dosage forms can give a rapid therapeutic effect from an immediate-release layer and extended dosing from a sustained-release layer, eliminating the need for repeat dosing.

Meet our modified release experts

Our partnership is focused on a single goal: Delivering new treatments to those in need, as efficiently and quickly as possible, with no compromises to product quality or patient safety. Meet some of the team members you’ll collaborate with on your next project.

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Dr. Asma Patel

VP, Integrated Development Services

Dr. Asma Patel is responsible for providing scientific and technical support to Quotient Sciences' business development group and ...

About Asma
Dr. Vanessa Zann

VP, Scientific Consulting, Translational Pharmaceutics & Clinical Pharmacology - USA

Dr. Vanessa Zann has over twenty-five years industry experience providing expert biopharmaceutic support to drug discovery, early ...

About Vanessa
John McDermott

VP, Scientific Consulting

John McDermott leads Quotient Sciences' global drug development consulting, research fellows, modeling & simulation, and clien...

About John
Let's Talk
Humanity can't wait, so neither can we. Discuss your drug program today.